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Abstract
Introduction: Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other
serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects
of CTX preventive therapy on tuberculosis (TB) remain unclear.
Methods: Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretrovi-
ral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival
after cART initiation were analysed using Cox regression, stratified by site.
Results: A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the
study. There were 368 reported cases of TB after cohort entry with an incidence rate of 0.99 per 100 person-years
(/100 pys). Multivariate analyses adjusted for viral load (VL), CD4 count, body mass index (BMI) and cART duration showed
that CTX reduced the hazard for new TB infection by 28% (HR 0.72, 95% CI l 0.56, 0.93). Mortality after cART initiation was
0.85/100 pys, with a median follow-up time of 4.63 years. Predictors of survival included age, female sex, hepatitis C co-infec-
tion, TB diagnosis, HIV VL, CD4 count and BMI.
Conclusions: CTX was associated with a reduction in the hazard for new TB infection but did not impact survival in our Asian
cohort. The potential preventive effect of CTX against TB during periods of severe immunosuppression should be further
explored.
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1 | INTRODUCTION
Cotrimoxazole (CTX) has been recommended as prophylaxis
against Pneumocystis jiroveci pneumonia (PJP), toxoplasmosis,
malaria and other serious bacterial infections in adults with
severe or advanced HIV clinical disease, with a CD4 count
less than 350 cells/lL or less than 200 cells/lL (depending on
region), by the World Health Organization (WHO) [1,2].
Although antituberculous effects of sulphonamides were iden-
tified in the late 1930s, their use in treatment against tuber-
culosis (TB) was basically forgotten because of the toxicity of
the early sulphonamides and that isoniazid and streptomycin
were stronger drugs [3,4]. However, in a previous study, the
majority of clinical isolates of Mycobacterium tuberculosis (Mtb)
from different patients were found sensitive to CTX [5]. Fur-
ther studies demonstrated sulphamethoxazole, instead of
trimethoprim, had in vitro bacteriostatic activity against Mtb
[6,7]. Not until recently had their potential role in treatment
or prophylaxis against TB been a major consideration in their
use in patients with HIV who may be taking CTX for PJP pro-
phylaxis. The first randomized controlled trial conducted in
Co^te d’Ivoire has demonstrated that daily CTX prophylaxis
was well tolerated and significantly decreased mortality and
hospital admission rates in HIV-infected patients with
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pulmonary tuberculosis [8]. A recent randomized controlled
trial in Cambodia has found that absence of CTX prophylaxis
in HIV-infected adult patients with smear-positive tuberculosis
was associated with an increased rate of late mortality [9].
Several cohort studies also found a decreased risk of death in
TB/HIV-coinfected patients receiving CTX preventive therapy
in resource-limited settings [10,11]. A Swiss HIV Cohort Study
suggested CTX reduced the incidence of TB among HIV-
infected persons, and although a recent case–control study in
Ethiopia also found CTX had a protective effect against TB
[12,13], findings from a South African cohort study did not
support a preventive effect [14]. This study aims to examine
the incidence of TB and survival in HIV-infected patients
receiving and not receiving CTX prophylaxis in a regional
observational cohort in Asia.
2 | METHODS
2.1 | Study population
Patients were included if they were enrolled in the adult
(age ≥ 18 years) TREAT Asia HIV Observational Database
(TAHOD) of IeDEA Asia-Pacific from 2003 and had initiated
combination antiretroviral therapy (cART). Patients who had
not initiated cART or those who initiated with mono/dual ther-
apy were excluded. All patients were analysed based on the
intention-to-treat approach where patients were considered
to be on cART for the entire follow-up time after cART had
been initiated, regardless of whether treatment interruptions
had occurred.
2.1.1 | Analysis (i): Factors associated with first TB
diagnosis after TAHOD entry
Patients were included if they had at least one day of follow-
up after cohort entry. TB diagnosis is defined as definitive
when there is isolation (or culture) of Mtb complex from a
clinical specimen. TB is presumptively diagnosed when there is
demonstration of acid-fast bacilli in a clinical specimen, or in a
histopathological lesion when a culture is not available, in a
person with signs or symptoms compatible with tuberculosis;
or evidence of resolution of disease where treatment with
two or more antituberculosis medications have been pre-
scribed and follow-up has been instigated. These diagnostic
criteria have been used in TAHOD and published previously
elsewhere [15-17]. A TB diagnosis up to seven days after
cohort entry was included as prior TB events [16]. Patients
without evidence of TB diagnosis during follow-up but have
died with TB as the reported cause of death were also
included as being diagnosed with TB on the date of death.
Risk time for TB started from the date of cohort entry and
ended on the date of TB diagnosis, defined as the outcome of
this analysis. Factors associated with TB diagnosis after cohort
entry was analysed using Cox regression, stratified by site.
Patients who did not develop TB were censored at date of
last follow-up. A TB diagnosis event could occur at any time
either before or after cART initiation, but post-cohort enrol-
ment. Time-fixed covariates included in the regression analysis
were age at cohort entry, sex, HIV exposure category, hepati-
tis B/C co-infection and a history of prior TB events. Time-
updated covariates were viral load (VL), CD4 count, body
mass index (BMI), cART duration, and CTX and isoniazid use.
Age, VL, CD4 and BMI were included as categorical variables
based on clinically relevant categories for our patient group as
well as taking into consideration the distribution of our data.
Age was categorized into 10-year groups to illustrate the
effects of hazard ratios (HRs) for each decade between 30
and 50 years of age. Viral load was categorized to represent
different levels of detectable and undetectable viral loads
[18,19]. CD4 cell count represented the different low levels
below 200 cells/lL at which CTX was initiated. BMI cate-
gories were grouped as “overweight” and “not overweight.” If
CTX or isoniazid was initiated in the 60 days prior to the
diagnosis of a new TB diagnosis, the TB episode was coded as
not exposed to CTX or isoniazid because these drugs may
have been started as a result of TB symptoms rather than as
preventative measures [14].
2.1.2 | Analysis (ii): Survival time after cART initiation
Patients who had at least one day of follow-up after cohort
entry or cART initiation (whichever occurred last) were eligi-
ble for inclusion in the analysis. Risk time for mortality after
cART initiation began from the date of cART initiation and
ended on the date of death or date of last follow-up. For
patients who initiated cART prior to cohort entry, survival
time was left-truncated at cohort entry. Survival time was
analysed using Cox regression, stratified by site. Time-fixed
covariates were age at cART initiation, sex, HIV exposure cat-
egory and hepatitis B/C co-infection. Time-updated covariates
were new TB diagnosis after cohort entry, VL, CD4 count,
BMI, and CTX and isoniazid use, which were coded in the
same way as Analysis (i).
All regression models were fitted using a backward step-
wise selection process. Covariates significant at p < 0.10 in
the univariate analyses were chosen for inclusion in the multi-
variate models. Covariates with p < 0.05 were considered sta-
tistically significant in the final model. Non-significant
covariates were presented in the tables adjusted for signifi-
cant predictors; however, they did not form part of the final
multivariate model. Crude incidence rates for TB diagnosis
and mortality were plotted for CTX by time-updated CD4 cell
count category. Cox proportional hazards (PH) assumption
was tested using Schoenfeld residuals and log–log plots.
2.2 | Sensitivity analyses
Several sensitivity analyses were performed to further assess
the association with TB diagnosis:
Sensitivity analysis (a) and (b): TB diagnosis was further
classified as presumptive or definitive. Those with unre-
ported TB classification were grouped into “presumptive” TB
cases. Fine and Gray competing risk regression, adjusted for
site, was used to analyse factors associated with presump-
tive TB (sensitivity analysis (a)) and definitive TB (sensitivity
analysis (b)).
Sensitivity analysis (c) and (d): Risk factors for TB diagnosis
was analysed separately for males (sensitivity analysis (c) and
females (sensitivity analysis (d)), using Cox regression meth-
ods, stratified by site.
Ethics approvals were obtained from the local institutional
review boards of each TAHOD-participating site, the data
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management and biostatistics centre (UNSW Sydney Ethics
Committee) and the coordinating centre (TREAT Asia/
amfAR). The informed consent was obtained or waived
according to the regulation from the local institutional
review boards of each TAHOD-participating site. All data
management and statistical analyses were performed using
SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA)
and Stata software version 14.1 (StataCorp, College Station,
TX, USA).
3 | RESULTS
A total of 8718 patients were enrolled in TAHOD as of
March 2015. There were 7465 patients (86%) who had initi-
ated with three or more cART. Of the 7465 patients, 7355
had at least one day of follow-up from cohort enrolment and
were included in Analysis (i). A total of 7328 patients were
included in Analysis (ii) as they had at least one day of follow-
up from the latter of cohort enrolment date or date of cART
initiation (Figure 1).
3.1 | Analysis (i): Factors associated with first TB
diagnosis after cohort entry
A total of 7355 patients from Cambodia, China, Hong Kong
SAR, India, Indonesia, Japan, Malaysia, Philippines, Singapore,
South Korea, Taiwan, Thailand and Vietnam were included
between 2003 and 2015. Of the 7355 patients, 5150 (70%)
were male, 3205 (44%) were aged between 31 and 40 years,
4682 (64%) acquired HIV through heterosexual exposure,
5050 (89% of 5644 tested) had no hepatitis B co-infection,
4544 (85% of 5331 tested) had no hepatitis C co-infection
and 5856 (80%) had no prior TB diagnosis (Table 1). There
were 368 (5%) new cases of TB reported after cohort entry
with an incidence rate of 0.99/100 person-years (100 pys).
The median follow-up time up to the TB diagnosis event was
4.6 years (interquartile range (IQR) 2.8 to 7.0). Of the 368 TB
cases, 125 (34%) were presumptive, 141 (38%) were defini-
tive and 102 (28%) did not report TB diagnosis category.
There was a total of 26 patients who had died due to TB, but
without prior evidence of TB diagnosis recorded in the data-
base after cohort enrolment. The median CD4 cell count at
time of TB diagnosis was 164 cells/lL (IQR 58 to 287) for
presumptive TB, 205 cells/lL (IQR 89 to 336) for definitive
TB and 162 cells/lL (IQR 25 to 293) for unknown category
TB cases.
In the univariate analyses, sex (p = 0.031), VL (p < 0.001),
CD4 count (p < 0.001), BMI (p < 0.001), cART duration
(p < 0.001) and CTX use (p < 0.001) were significantly associ-
ated with incident TB diagnosis. In multivariate analyses,
higher VL (1000 to 4999 copies/mL HR 2.18, 95% CI (1.06
to 4.48), p = 0.034; and ≥ 5000 copies/mL HR 2.38, 95% CI
(1.63 to 3.47), p < 0.001) were associated with increased haz-
ard of developing TB compared to VL < 400 copies/mL. Con-
versely, higher CD4 count (51 to 100 cells/lL HR 0.57, 95%
CI (0.38 to 0.86), p = 0.007; 101 to 200 cells/lL HR 0.42,
95% CI (0.30 to 0.58), p < 0.001; and > 200 cells/lL HR
0.11, 95% CI (0.08 to 0.15), p < 0.001) was associated with
reduced hazard for TB compared to CD4 ≤ 50 cells/lL. Other
factors associated with reduction in hazard for development
of TB were BMI ≥ 25 kg/m2 (HR 0.46, 95% CI (0.31 to 0.69),
p < 0.001) compared to BMI < 25 kg/m2; longer cART dura-
tions (6 to 12 months HR 0.47, 95% CI (0.28 to 0.80),
p = 0.005; and > 12 months HR 0.40, 95% CI (0.28 to 0.57),
p < 0.001) compared to periods prior to cART initiation; and
Figure 1. Flow diagram.
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diagnosis Rate (/100 pys)
Univariate Multivariatea
HR (95% CI) p-valuec HR (95% CI) p-valuec,d
Total 7355 368 0.99
Age at TAHOD entry (years)
≤30 1982 100 1.07 1 0.944 1 0.118
31 to 40 3205 175 1.05 1.13 (0.88, 1.45) 0.328 1.30 (1.01, 1.67) 0.042
41 to 50 1513 73 0.94 1.14 (0.83, 1.55) 0.418 1.47 (1.07, 2.01) 0.018
>50 655 20 0.59 0.82 (0.50, 1.33) 0.422 1.05 (0.64, 1.73) 0.842
Sex
Male 5150 280 1.08 1 1
Female 2205 88 0.78 0.76 (0.59, 0.98) 0.031 0.79 (0.62, 1.01) 0.064
HIV exposure
Heterosexual contact 4682 253 1.03 1 0.125 1 0.501
Homosexual contact 1580 50 0.63 0.77 (0.52, 1.12) 0.176 0.88 (0.60, 1.30) 0.527
Injecting drug use 555 41 1.99 1.49 (0.97, 2.29) 0.067 1.34 (0.87, 2.06) 0.182
Other/Unknown 538 24 0.88 0.90 (0.57, 1.42) 0.661 0.96 (0.61, 1.51) 0.870
Hepatitis B co-infection
Negative 5050 234 0.9 1 1
Positive 594 26 0.86 1.11 (0.74, 1.67) 0.624 1.07 (0.71, 1.62) 0.738
Not tested 1711 108 1.33
Hepatitis C co-infection
Negative 4544 186 0.77 1 1
Positive 787 42 1.27 1.38 (0.94, 2.04) 0.102 1.28 (0.86, 1.90) 0.217
Not tested 2024 140 1.45
Prior TB
No 5856 239 0.8 1 1
Yes 1499 129 1.77 1.34 (1.06, 1.68) 0.013 1.22 (0.97, 1.54) 0.094
Viral load (copies/mL)
<400 – 76 0.3 1 <0.001 1 <0.001
400 to 999 – 3 0.55 1.45 (0.45, 4.63) 0.534 1.02 (0.32, 3.26) 0.979
1000 to 4999 – 9 1.24 3.07 (1.51, 6.26) 0.002 2.18 (1.06, 4.48) 0.034
≥5000 – 100 2.93 5.35 (3.77, 7.60) <0.001 2.38 (1.63, 3.47) <0.001
Missing – 180 2.47
CD4 (cells/lL)
≤50 – 78 9.91 1 <0.001 1 <0.001
51 to 100 – 35 4.05 0.49 (0.33, 0.74) 0.001 0.57 (0.38, 0.86) 0.007
101 to 200 – 77 2.18 0.33 (0.24, 0.46) <0.001 0.42 (0.30, 0.58) <0.001
>200 – 158 0.5 0.09 (0.06, 0.12) <0.001 0.11 (0.08, 0.15) <0.001
Missing – 20 3.58
BMI (kg/m2)
<25 – 265 1.09 1 1
≥25 – 27 0.46 0.39 (0.26, 0.58) <0.001 0.46 (0.31, 0.69) <0.001
Missing – 76 1.09
cART duration
Prior to cART initiation – 53 3.2 1 <0.001 1 <0.001
<6 months – 84 5.43 1.72 (1.15, 2.58) 0.008 1.08 (0.70, 1.66) 0.727
6 to 12 months – 29 1.45 0.54 (0.32, 0.89) 0.015 0.47 (0.28, 0.80) 0.005
>12 months – 202 0.63 0.33 (0.24, 0.46) <0.001 0.40 (0.28, 0.57) <0.001
Cotrimoxazole use
No – 231 0.75 1 1
Yes – 137 2.13 1.71 (1.36, 2.15) <0.001 0.72 (0.56, 0.93) 0.011
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CTX use (HR 0.72, 95% CI (0.56 to 0.93), p = 0.011)
(Table 1). We found that the hazard for CTX was reversed
after adjusting for CD4 count (from HR 1.71 to HR 0.72),
indicating possible confounding by CD4 levels. When tested
for PH assumption, it was noted that CD4 levels violated the
assumption at early time periods. We have therefore stratified
the analysis by both CD4 and site to account for this violation
(Table S1). The multivariate results were similar to those
obtained in Table 1 suggesting that the violation of the PH
assumption was minor and did not have a great impact on our
results.
The crude TB incidence rates in those receiving and not
receiving CTX, stratified by CD4 count, are shown in Figure 2.
Overall, the incidence of TB decreased with increasing CD4
cell count. Among patients with CD4 ≤ 50 cells/lL, the inci-
dence was lower in those receiving CTX (7.7/100 pys) com-
pared those not receiving CTX (13.3/100 pys) (p = 0.002). To
explore this further, we performed a univariate analysis by
including CTX and limiting the analyses to each CD4 cell
count category while taking into account heterogeneity across
sites. We found that CTX use at CD4 ≤ 50 cells/lL was asso-
ciated with reduced hazard for TB compared to those not
receiving CTX within the same CD4 ≤ 50 cells/lL category:
HR = 0.37, 95% CI (0.21 to 0.65), p < 0.001. No significant
difference was found in those receiving CTX at CD4 51 to
100 cells/lL (HR = 0.47, 95% CI (0.19 to 1.16), p = 0.102).
For those taking CTX at CD4 101 to 200 cells/lL, there was
a 44% reduction in the hazard for development of TB
(HR = 0.56, 95% CI (0.33 to 0.94), p = 0.03) compared to
those no receiving CTX. No significance difference was found
for among those with CD4 > 200 cells/lL HR = 1.30, 95% CI
(0.85 to 2.00), p = 0.222. In summary, CTX was associated
with reduced hazards for TB among those with current
CD4 ≤ 50 cells/lL and 101 to 200 cells/lL.
3.2 | Analysis (ii): Survival time after cART initiation
A total of 7328 patients were included in the survival analysis
(Table 2). The mortality rate was 0.85/100 pys, with a median
follow-up time of 4.63 years (IQR 2.80 to 6.92 years). In the
adjusted model, factors associated with poorer survival were
older age (41 to 50 years HR 1.49, 95% CI (1.05 to 2.13),
p = 0.027; and > 50 years HR 3.90, 95% CI (2.70 to 5.62),
p < 0.001) compared to age ≤ 30 years; being hepatitis C
antibody positive (HR 1.90, 95% CI (1.33 to 2.72), p < 0.001);
having an incident TB diagnosis (HR 2.50, 95% CI (1.73
to 3.63), p < 0.001); and having VL ≥ 5000 copies/mL (HR
1.59, 95% CI (1.09 to 2.34), p = 0.017) compared to
VL < 400 copies/mL. Factors associated with improved sur-
vival were female sex (HR 0.70, 95% CI (0.53 to 0.94),
p = 0.017); higher CD4 count (51 to 100 cells/lL HR 0.42,
95% CI (0.29 to 0.62); 101 to 200 cells/lL HR 0.19, 95% CI
(0.13 to 0.28); and > 200 cells/lL HR 0.06, 95% CI (0.04 to
0.09), all p < 0.001) compared to CD4 ≤ 50 cells/lL; and
BMI ≥ 25 kg/m2 (HR 0.40, 95% CI (0.24 to 0.68), p = 0.001)
compared BMI < 25 kg/m2. Those using CTX also had
improved survival; however, this effect was not statistically
significant (HR 0.78, 95% CI (0.58 to 1.03, p = 0.081). Crude
mortality rates in those receiving and not receiving CTX, strat-
ified by CD4 count, are shown in Figure 3. The hazard for
mortality was only significantly lower in those receiving CTX
at CD4 101 to 200 cells/lL (HR = 0.51, 95% CI (0.28 to
0.94), p = 0.031).
3.3 | Sensitivity analyses (a) and (b)
Table S2 shows competing risk analysis of factors associated
with having presumptive TB diagnosis after cohort entry, with
definitive TB analysed as a competing risk (sensitivity analysis
(a)). Of the 7355 patients, 227 met the definition of presump-
tive TB outcome for this sensitivity analysis, which included





diagnosis Rate (/100 pys)
Univariate Multivariatea
HR (95% CI) p-valuec HR (95% CI) p-valuec,d
Isoniazid use
No – 353 0.98 1 1
Yes – 15 1.31 1.20 (0.69, 2.08) 0.520 1.12 (0.64, 1.97) 0.684
aNon-significant covariates were presented in the final model adjusted for the significant covariates; however, they did not form part of the final
model; bviral load, CD4, BMI, cART duration, cotrimoxazole and isoniazid use are time-updated variables; cglobal p-values for age, VL and CD4 are
tests for trend. All other global p-values are tests for heterogeneity excluding missing values; dp-values in bold represent significant covariates in
the final model.
Figure 2. TB incidence.
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Table 2. Survival time after cART initiation
Number of patientsb Deaths Rate (/100 pys)
Univariate Multivariatea
HR (95% CI) p-valuec HR (95% CI) p-valuec,d
Total 7328 315 0.85
Age at ART initiation (years)
≤30 2309 74 0.68 1 <0.001 1 <0.001
31 to 40 3110 116 0.71 1.12 (0.83, 1.50) 0.473 1.13 (0.84, 1.53) 0.419
41 to 50 1347 64 0.92 1.40 (0.99, 1.97) 0.056 1.49 (1.05, 2.13) 0.027
>50 562 61 2.16 3.40 (2.39, 4.84) <0.001 3.90 (2.70, 5.62) <0.001
Sex
Male 5132 249 0.97 1 1
Female 2196 66 0.59 0.58 (0.44, 0.78) <0.001 0.70 (0.53, 0.94) 0.017
HIV exposure
Heterosexual contact 4665 214 0.87 1 <0.001 1 0.204
Homosexual contact 1573 42 0.55 0.42 (0.28, 0.63) <0.001 0.64 (0.42, 0.98) 0.039
Injecting drug use 554 35 1.65 1.69 (1.10, 2.58) 0.016 0.98 (0.60, 1.60) 0.939
Other/unknown 536 24 0.9 0.85 (0.53, 1.34) 0.482 1.02 (0.63, 1.63) 0.946
Hepatitis B co-infection
Negative 5036 193 0.75 1 1
Positive 591 36 1.19 1.53 (1.07, 2.20) 0.019 1.39 (0.96, 2.01) 0.078
Not tested 1701 86 1.06
Hepatitis C co-infection
Negative 4536 172 0.72 1 1
Positive 786 53 1.61 2.31 (1.64, 3.26) <0.001 1.90 (1.33, 2.72) <0.001
Not tested 2006 90 0.94
New TB diagnosis after TAHOD entry
No – 276 0.78 1 1
Yes – 39 2.94 3.82 (2.68, 5.43) <0.001 2.50 (1.73, 3.63) <0.001
Viral load (copies/mL)
<400 – 130 0.49 1 <0.001 1 0.012
400 to 999 – 3 0.51 0.97 (0.30, 3.08) 0.958 0.69 (0.21, 2.24) 0.537
1000 to 4999 – 6 0.98 1.76 (0.76, 4.10) 0.189 1.23 (0.53, 2.86) 0.638
≥5000 – 84 2.68 3.89 (2.68, 5.64) <0.001 1.59 (1.09, 2.34) 0.017
Missing – 92 1.54
CD4 (cells/lL)
≤50 – 89 10.39 1 <0.001 1 <0.001
51 to 100 – 42 4.47 0.43 (0.30, 0.64) <0.001 0.42 (0.29, 0.62) <0.001
101 to 200 – 60 1.65 0.17 (0.12, 0.25) <0.001 0.19 (0.13, 0.28) <0.001
>200 – 115 0.37 0.04 (0.03, 0.06) <0.001 0.06 (0.04, 0.09) <0.001
Missing – 9 2.83
BMI (kg/m2)
<25 – 229 0.93 1 1
≥25 – 16 0.28 0.33 (0.20, 0.55) <0.001 0.40 (0.24, 0.68) 0.001
Missing – 70 1.07
Cotrimoxazole use
No – 200 0.66 1 1
Yes – 115 1.76 1.91 (1.46, 2.51) <0.001 0.78 (0.58, 1.03) 0.081
Isoniazid use
No – 301 0.84 1 1
Yes – 14 1.21 1.71 (0.96, 3.07) 0.070 1.56 (0.86, 2.84) 0.142
aNon-significant covariates were presented in the final model adjusted for the significant covariates; however, they did not form part of the final model;
bTB diagnosis, viral load, CD4, BMI, cotrimoxazole and isoniazid use are time-updated variables; cglobal p-values for age, VL and CD4 are tests for trend.
All other global p-values are tests for heterogeneity excluding missing values; dp-values in bold represent significant covariates in the final model.
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0.61/100 pys. In the multivariate model, we saw similar risk
factors and effect sizes as in Table 1, with hepatitis C
co-infection (subhazard ratio (SHR):1.69, 95% CI (1.08 to
2.65), p = 0.022) and prior TB diagnosis (SHR = 1.37, 95% CI
(1.02 to 1.85), p = 0.039) being associated with having pre-
sumptive TB. In sensitivity analysis (b), where we analysed
factors associated with definitive TB, with presumptive TB
as a competing risk, the incidence rate was 0.38/100 pys
(Table S3). Due to the small number of events in this
analysis, only VL, CD4 and age were associated with defini-
tive TB diagnosis. However, when comparing the results
across all three analyses (Table 1, Tables S2 and S3), the
effects of each variable were similar, with CTX showing
reduction in hazards for TB after adjusting for CD4 cell
count.
3.4 | Sensitivity analyses (c) and (d)
We assessed factors associated with TB diagnosis separately
in males and females. Of the 5150 males, 280 (5%) were diag-
nosed with TB after cohort enrolment, with an incidence rate
of 1.08/100 pys (Table S4). Among 2205 females, there were
88 patients (4%) with TB diagnosis, with an incidence rate of
0.78/100 pys (Table S5). In males, being hepatitis C coin-
fected and having high VL were associated with having TB.
Males with high CD4 cell count, BMI above 25 kg/m2, been
on cART for longer than six months, and receiving CTX had
reduced hazards for TB. For females, similar effects were
seen; however, hepatitis C co-infection and CTX were no
longer significantly associated with TB.
4 | DISCUSSION
Our analysis found that cotrimoxazole preventive therapy
reduced the hazard for incident TB infection by approximately
one-third in HIV-infected adult patients, adjusted for HIV viral
load, CD4 count, BMI and cART duration. This adds to clinical
evidence supporting the potential additive preventive effect of
CTX against tuberculosis in HIV-infected individuals [12,13].
We also found CTX was associated with reduced hazards for
TB among those with current CD4 ≤ 50 and 101 to
200 cells/lL.
Previous clinical trials have shown that CTX prophylaxis
reduced mortality and hospital admission for septicaemia and
enteritis in HIV/TB-coinfected patients in West Africa, as well
as death including tuberculosis and other HIV-associated con-
ditions in Southeast Asia [8, 9]. Such benefits are likely due to
a vast array of antibacterial, antifungal, and antiparasitic
effects from CTX. In addition, sulphamethoxazole has been
found active against Mtb in vitro [5-7]. Several observational
studies including ours suggested CTX decreased new TB inci-
dence in HIV-infected individuals, supporting a direct antitu-
bercular effect from CTX [12,13].
Our findings that higher BMI, greater CD4 cell count, and
duration of receiving antiretroviral therapy more than six
months were associated with lower incidence of new TB infec-
tion were also comparable to other studies [12-14]. The find-
ing that a higher HIV viral load, regardless cART or CD4 cell
count was independently associated with an increased risk of
new TB infection, is consistent with a previous study in Spain,
suggesting that a high HIV viral load in treatment-na€ıve
patients, in patients with treatment interruption or even in
treatment-experienced patients with a failing antiretroviral
regimen may be linked to an increased occurrence of active
TB [20].
The reversal of the HRs for CTX once CD4 cell count was
adjusted for reflects the confounding of CTX by CD4 cell
count. CTX is normally prescribed as primary prophylaxis in
patients with CD4 < 200 cells/lL [1], who are more likely to
have poorer treatment outcomes. When CTX was analysed in
the univariate analysis, the increased hazard for incident TB in
those receiving CTX simply reflected the underlying confound-
ing of increased TB in those with low CD4 counts. Once the
confounding CD4 levels were controlled for in the multivari-
ate analysis, that is once we compared the effects of CTX in
patients within the same CD4 category, it was evident that
CTX reduced the hazard for TB diagnosis.
Many studies have shown that CTX preventive therapy
reduces mortality in HIV-infected patients [21,22]. A previous
TAHOD study showed greatest absolute survival benefit from
PJP prophylaxis, predominantly with CTX, in patients with a
CD4 count less than 50 cells/lL [23]. While this study showed
improved survival in those using CTX, the effect was only sta-
tistically significant in people with current CD4 101 to
200 cells/lL, possibly due to attenuation of the benefit by
including only patients who had initiated cART in the current
analysis.
We did not find differences in survival time according to
isoniazid use in the multivariate analyses, which was likely due
to the small number of patients that had actually received iso-
niazid preventive therapy (IPT) in our cohort. This finding
might also reflect the fact that IPT is not delivered uniformly
by physicians in concordance with WHO or local guidelines in
our region [24].
While our study analysed data on a substantial number of
patients from a prospective cohort in a region where TB bur-
den is high, several important limitations are noted. Firstly, not
all new TB cases were laboratory-confirmed with positive cul-
ture results since we used both definite and presumptive defi-
nitions for TB diagnosis. While this helps to avoid
underascertainment of TB cases, we may have missed other
Figure 3. Mortality rates.
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patients who were unknown to be receiving care outside of
the HIV clinical setting. We also performed sensitivity analy-
ses, and the effects of each variable were similar in new cases
with both definite and presumptive TB diagnosis. Tuberculin
skin testing (TST) results were not recorded in our cohort
thus patients with possible latent TB infection were not
excluded from the analyses. Although the prescription of
prophylactic CTX was documented, we did not specifically
assess adherence to CTX or precise dosage of CTX in our
cohort sites. A recent pharmacokinetic/pharmacodynamic
study showed that the serum level of sulphamethoxazole is
comparable with other drugs with anti-TB activity, like pyrazi-
namide, at a standard prophylactic dose of 960 mg CTX once
daily, as recommended by WHO [25]. As we have considered
TB diagnosis within 60 days of initiation of CTX to be consid-
ered as not exposed to CTX, this may accentuate the protec-
tive effect of CTX if TB cases were diagnosed soon after
cART initiation. Lastly, the susceptibility test results to CTX or
other antimycobacterial agents for the microbiologic isolates
were not collected in our TAHOD database. Nevertheless,
other studies have shown that the minimal inhibitory concen-
tration of sulphamethoxazole is not significantly different in
patients infected with MDR-TB or drug-susceptible TB and
that resistance to sulphamethoxazole was not frequent in TB/
HIV-coinfected patients taking CTX prophylaxis [26,27].
5 | CONCLUSIONS
Our study found that cotrimoxazole preventive therapy was
associated with a reduction in the hazard for incident TB
infection among Asian patients in our cohort, adding to exist-
ing clinical evidence supporting the use of CTX in HIV-
infected patients for broader prevention purposes.
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